To evaluate the impact of the activation of ERBB4 on proliferation and motility of HER2+ breast cancer cells, avoiding the undesired activation of ERBB3, we thus employed neuregulin 4 (NRG4), which specifically binds only ERBB4 (48) [reviewed in (1–3, 30)]. Here, NRG4 is linked to breast cancer.